, United Therapeutics Corporation (Nasdaq: UTHR)
announced today that the Drug Registration Department of the Israeli Ministry
of Health has expanded the label of Remodulin(R) (treprostinil sodium)
Injection to include intravenous infusion for the treatment of primary
pulmonary arterial hypertension and pulmonary arterial hypertension associated
with connective tissue disorders.
The Israeli approval represents the third national approval of intravenous
Remodulin following United States Food and Drug Administration approval on
November 24, 2004 and the Canadian Therapeutic Products Directorate approval
on October 6, 2005.D.
The live presentation begins at 11:30 a.m.neurocrine. Our product
candidates address some of the largest pharmaceutical markets in the world
including insomnia, anxiety, depression, diabetes, irritable bowel syndrome,
and autoimmunity .com, is a leading
proteomics company engaged in the discovery of protein footprints, pathways,
and mechanisms of diseases. Any statements in this press release, which are not
statements of historical fact, may be deemed to be forward-looking statements.

q infectious

Live Audio Webcast Wednesday, April 5, 2006

SAN DIEGO, Neurocrine Biosciences,
Inc.
Pacific Time (PT) with Gary Lyons presenting an overview of the Company's
development pipeline and research programs.
A replay of the webcast will be available approximately three hours after
the presentation concludes and will be archived until Wednesday, April 19,
2006.com

"Neurodegenerative diseases are difficult to diagnose, particularly in
their early stages, because currently there are no objective blood serum tests
available for the early diagnosis of these diseases," said Steven Rash,
chairman and chief executive officer.

rickettsial isaacs

and RESEARCH TRIANGLE PARK, N.C., (Nasdaq: NBIX) a biopharmaceutical company focused on neurological and
endocrine diseases and disorders announced today that Gary Lyons, President
and CEO will present at the CIBC Annual Biotechnology + Specialty
Pharmaceutical Conference Wednesday , April 5, 2006 at the Millennium Broadway
Hotel in New York. The patent
application is being filed in conjunction with major research institutions in
the Houston area, with Power3 having an exclusive license to commercialize the
technology involved.
This press release contains "forward -looking" statements, including
statements related to the outcome of certain actions being taken by the
Company and the anticipated timing and nature of filings with the Securities
and Exchange Commission.

diseases muscle

United Therapeutics has also submitted a marketing
application for intravenous Remodulin in France, with filings in additional
countries planned during 2006.

Neurocrine Biosciences to Present at the CIBC Annual Biotechnology + Specialty Pharmaceutical Conference

Neurocrine Biosciences, Inc. news releases are available
through the Company's website via the Internet at http://www.

q conditions

These expectations
are subject to risks and uncertainties such as those described in United
Therapeutics ' periodic reports filed with the Securities and Exchange
Commission which may cause actual results to differ materially from
anticipated results. United Therapeutics is providing this information as
of January 10, 2006 and undertakes no obligation to publicly update or revise
the information contained in this press release whether as a result of new
information, future events or any other reason.

Viewers are encouraged to visit the website approximately 5 minutes
prior to the presentation to download or install any necessary software. "Our objective is to obtain patent
protection for Power3's intellectual property rights used in tests measuring
changes among groups of biomarkers for the early detection of neurological
diseases.

About Power3 Medical Products
Power3 Medical Products, http://www.

neurological infectious

, United Therapeutics
Chairman and CEO.

Neurocrine Biosciences, Inc. The Company's patent-pending technologies are
being used to develop screening and diagnostic tests for the early detection
and treatment of disease. Power3 assumes no obligation to update forward-looking statements as a
result of new information, future events or otherwise.

rickettsial squander

Israeli Ministry of Health Approves Intravenous Dosing of Remodulin(R) to Treat Pulmonary Arterial Hypertension

"We and our Israeli distribution partner, Pharmateam Marketing, are very
pleased with this authorization to offer intravenous Remodulin to patients and
physicians in Israel," said Martine Rothblatt, Ph.

In addition to historical information, this press release contains
forward -looking statements about expectations and intentions regarding the
preparation and filing of marketing applications for intravenous Remodulin in
additional countries during 2006 that are based on United Therapeutics'
current beliefs and expectations as to future outcomes. (OTC Bulletin Board: PWRME ) announced today that it has filed a
provisional patent application with the United States Patent and Trademark
Office for the Company's first generic, blood-based diagnostic test for
neuromuscular disorders such as ALS and Parkinson's disease. We believe that patent protection for the diagnosis of
neuromuscular disorders will prove to be a strong asset in the Company's ever
growing intellectual property portfolio, and thereby, serve to enhance
shareholder value."
Power3's test comprises collecting a blood sample from a patient,
separating the proteins present in the sample, analyzing a panel of protein
biomarkers using proteomic techniques, and determining whether or not the
patient has a neuromuscular disease based on the quantity of the biomarkers in
the patient's sample combined with biostitistical analysis.

isaacs neurological

diseases health

Eastern Time (ET) / 8:30 a. The Company's identified protein biomarkers , drug
targets, and diagnostic tests are targeted toward markets with critical unmet
needs in areas such as breast cancer and neurodegenerative disease.

rickettsial infectious

"Since 2002 the Israeli market has been an important
trailblazer for United Therapeutics. The presentation will be webcast
and can be accessed on the Company's website at http://www. is a product-based biopharmaceutical Company
focused on neurological and endocrine diseases and disorders. - Blood-based Diagnostic Test Could Provide Means for Early Diagnosis of
Neuromuscular Diseases Such as ALS and Parkinson's -

THE WOODLANDS , Texas, Power3 Medical
Products, Inc.Power3Medical.

Contacts:
Corporate Investor Relations
Steven Rash Kathy Price
Chairman/CEO Managing Director
Power3 Medical Products, Inc .

diseases syndrome

"

United Therapeutics is a biotechnology company focused on the development
and commercialization of innovative therapeutic products for patients with
chronic and life-threatening cardiovascular , cancer and infectious diseases.m.neurocrine. The Company also
intends to extend the technology to high throughput immunodiagnostics suitable
for clinical laboratories and doctors' offices. The Anne McBride Company
T: 281-466-1600 Tel: 212-983-1702 x212

health neurological

com.
If you are unable to attend the webcast and would like further information
on this announcement please contact the Investor Relations Department at
Neurocrine Biosciences at 858 -617-7600 and ask for Claudia Woodworth or
Elizabeth Foster.
The Power3 intellectual property portfolio includes other pending patents,
provisional patent applications, research and license agreements with leading
medical research institutions in the areas of cancer, drug resistance,
metabolic syndrome, and neurodegenerative disease. The
Company operates a state-of-the-art proteomics laboratory in The Woodlands,
Texas.
Words such as "will," "expects," "anticipates," "plans," and similar
expressions are intended to identify these forward-looking statements. There
are a number of important factors and uncertainties that could cause results
to differ materially from those indicated by these forward-looking statements,
including risks inherent in research and development activities; the ability
to raise sufficient capital and obtain financing for the development
activities; uncertainties associated with regulatory approvals; as well as
other risks detailed from time to time in Power3 's reports filed with the
Securities and Exchange Commission, including its Annual Report on Form 10-KSB
for the year ended December 31, 2003, and its reports on Form 10-QSB and Form
8-K.

fever rickettsial

SILVER SPRING, Md. Consequently, such forward-looking statements are
qualified by the cautionary statements , cautionary language and risk factors
set forth in United Therapeutics' periodic reports and documents filed with
the Securities and Exchange Commission, including the company's most recent
Form 10 -K and Form 10-Q.